Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Biotechnology

Healthcare
$2.29 +0.67%

+$0.02 today

Market cap
$165.63M
Beta
0.35
P/E (TTM)
-1.3
EPS (TTM)
-$1.79
52W Low $1.10High $3.60

Volume 0.81M

Average 0.40M

ABOS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Acumen Pharmaceuticals, Inc.NASDAQ: ABOS

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$19.62M, compared with -$27.73M a year earlier. Trailing-twelve-month EBITDA was -$108.82M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -19.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$19.62M+18.3% QoQ
Last fiscal yearDec 2025
-$116.93M-19.2% YoY
LTMMar 2026
-$108.82M+2.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.2%+100.0%+70.8 pp
1 year-19.2%+100.0%+119.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(116.93M) USD
Year-over-year change
-19.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ABOS compares with its peers on the latest reported figures

  • ABOS's LTM Mar 2026 EBITDA of -$108.82M is the 8th highest of the 10 companies compared; the peer median is -$64.35M.
  • Its year-over-year change of +2.8% is the 8th highest of 10, against a peer median of +18.9%.
ABOS Competitors Peer median
EBITDA for ABOS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$127.04M +256.7%—102.6%
SPROSpero Therapeutics, Inc.LTM Mar 2026$14.89M +121.1%—27.2%
ACTUActuate Therapeutics IncLTM Mar 2026-$21.52M +14.5%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026-$41.87M +24.2%—3650.0%
SEERSeer, Inc.LTM Mar 2026-$64.35M +18.9%—427.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$81.94M +12.2%——
IRDOpus Genetics, Inc.LTM Mar 2026-$104.73M -226.0%—874.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$108.82M +2.8%——
ALECAlector, Inc.LTM Mar 2026-$116.42M -1.3%—632.1%
FATEFate Therapeutics, Inc.LTM Mar 2026-$117.42M +23.4%—1859.1%
Peer median (excluding ABOS) -$64.35M+18.9%—632.1%

Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue12.31M0000
Gross Profit(12.31M)0000
Gross Margin—————
Research & Development12.31M32.36M42.32M93.8M104.89M
Selling, General & Admin7.28M12.88M18.82M20.22M18.95M
Operating Expenses7.28M45.24M61.14M114.02M123.83M
Depreciation & Amortization4K169K184K178K184K
EBITDA(100.6M)(42.69M)(51.61M)(98.08M)(116.93M)
EBITDA Margin—————
Operating Income(19.58M)(45.24M)(61.14M)(114.02M)(123.83M)
Operating Margin—————
Interest Income84K2.39M10.79M14.32M7.45M
Interest Expense00581K4.07M4.22M
Other Income / Expenses(81.02M)2.38M8.77M11.69M2.5M
Income Before Tax(100.61M)(42.86M)(52.37M)(102.33M)(121.34M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(100.61M)(42.86M)(52.37M)(102.33M)(121.34M)
Net Margin—————
EPS (Basic)(2.63)(1.06)(1.08)(1.71)(2.00)
EPS (Diluted)(2.63)(1.06)(1.08)(1.71)(2.00)
Weighted Avg Shares38.27M40.6M48.49M60.01M60.56M
Weighted Avg Shares (Diluted)38.27M40.6M48.61M60.01M60.56M

Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

Intrinsic Alpha fair value

Locked

Current Price

$2.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.